Free tool
FAERS Monitor: Tobramycin Sulfate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050789 or its brand name (Tobramycin Sulfate, Tobramycin Sulfate). Reports on generic versions are filed under their own applications.
Reports
12,545
Serious
10,114
81% of reports
Hospitalization
6,073
Death reported
1,303
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pneumonia782
- off label use778
- drug ineffective710
- acute kidney injury690
- dyspnoea688
- infective pulmonary exacerbation of cystic fibrosis624
- death482
- infection465
- hospitalisation462
- cough458
- condition aggravated451
- cystic fibrosis430
- pyrexia428
- fatigue403
- nausea370
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 86 |
| 2005 | 104 |
| 2006 | 83 |
| 2007 | 133 |
| 2008 | 98 |
| 2009 | 104 |
| 2010 | 114 |
| 2011 | 213 |
| 2012 | 207 |
| 2013 | 171 |
| 2014 | 283 |
| 2015 | 449 |
| 2016 | 506 |
| 2017 | 561 |
| 2018 | 1,032 |
| 2019 | 1,557 |
| 2020 | 1,399 |
| 2021 | 1,030 |
| 2022 | 981 |
| 2023 | 832 |
| 2024 | 1,035 |
| 2025 | 894 |
| 2026 | 673 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,614 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 624 | 217.0 | 200.0 | 118,615 |
| cystic fibrosisSignal | 430 | 141.1 | 128.1 | 55,055 |
| acute kidney injurySignal | 690 | 7.6 | 7.1 | 3,952 |
| infectionSignal | 465 | 5.4 | 4.9 | 1,669 |
| hospitalisationSignal | 462 | 5.1 | 4.6 | 1,505 |
| pneumoniaSignal | 782 | 4.1 | 3.8 | 1,822 |
| coughSignal | 458 | 2.7 | 2.5 | 511 |
| condition aggravatedSignal | 451 | 2.5 | 2.3 | 406 |
| pyrexiaSignal | 428 | 2.1 | 1.9 | 241 |
| dyspnoeaSignal | 688 | 2.0 | 1.9 | 373 |
| off label use | 778 | 1.5 | 1.4 | 130 |
| death | 482 | 0.9 | 0.9 | 2 |
| drug ineffective | 710 | 0.9 | 0.8 | 8 |
| fatigue | 403 | 0.9 | 0.8 | 8 |
| nausea | 370 | 0.8 | 0.7 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.